Longitudinal change in clinical fracture incidence after initiation of bisphosphonates - Wikidata - wikimedia - TriplyDB

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

http://www.wikidata.org/entity/Q33819111

about

Risedronate's efficacy: from randomized clinical trials to real clinical practice.Osteoporosis therapies: evidence from health-care databases and observational population studies.Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007.Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study.Fracture incidence in a large cohort of men age 30 years and older with osteoporosis.Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Risk factors for fracture among current, persistent users of bisphosphonates.Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.

P2860

Q33965652-278EA7F1-7D2E-4D77-A246-8A7EE385AEA9 Q34242906-5B8E78F6-27E8-41BB-95BA-C2D5AE8E49A2 Q34440107-76EE2F9F-C4CA-49BD-BDE2-18B473658F2B Q35229889-72E9F135-09A4-4B39-855C-E176E8E0C3BD Q35598005-13E23563-E7D8-4FF3-B8CF-A612F56C2D30 Q38702184-A533B6F5-9601-47CB-92AF-1A385CF7E062 Q40300226-831C9E3A-8800-4A85-AD7F-AC1C4314E8A5 Q41534608-166700B5-9E1F-4F02-8CCE-19FBB052B6BD Q42108489-C2F3E2D1-0492-4B5C-9D5B-E7AB2225FF20 Q44381104-705A8A37-D6E9-4099-BA88-D03501F380BF Q44430151-3C88FCA9-006C-4296-B746-0B2522291765 Q46244082-6E0555B3-181A-4BD5-A773-F263D016A8F5 Q51736759-CBF324BB-4200-4C07-96B1-FF6AE4BAC5C8

P2860

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

http://www.wikidata.org/entity/Q33819111

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@ast

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@en

type

label

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@ast

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@en

prefLabel

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@ast

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@en

P1433

Q33819111-69A378EA-4EFA-4E1A-8C90-52A63528AD04

P1476

Q33819111-4F6CE256-8C96-4D28-9E62-F11D7777AFAF

P2093

Q33819111-4CB5C7E6-172F-43BC-AC32-5CCF060ED6A8

Q33819111-5CDAB809-4002-4837-8273-C882596AC30B

Q33819111-C1F8BC70-80FC-4BAD-A21D-42CF8A01C347

Q33819111-C9CECA1D-3BD5-43C5-8E04-288EF1D5080F

Q33819111-DC6A474D-3A82-4B34-B049-67919069C6F4

P2860

Q33819111-0955D459-44DD-4DC4-BB13-5D47A310364F

Q33819111-16459FA4-DF78-4E85-89FC-8D12B8F74AF6

Q33819111-17B111CB-A69A-4B05-AC28-01C3BC784858

Q33819111-1A76EE50-E6AF-475A-BCD9-A7330474F77F

Q33819111-1A7CFFF8-528C-4F25-A1FC-813DB52559CD

Q33819111-2DD44E9D-5880-4AB0-A99A-54ABCF83447C

Q33819111-417EEADB-A1FE-4993-B4C5-B30466CA83CF

Q33819111-419D6A23-FC75-4170-BA00-73C1E1B2FE1B

Q33819111-426DA4DD-9D1F-4C6F-BB80-6680D31BE5C7

Q33819111-42B1B597-E9C6-4630-8661-43C9DC35C770

P2888

Q33819111-A0AFD818-2BAB-4E91-A249-4A6C8ED1F09D

P304

Q33819111-6DA516A3-870A-4633-AB6B-52260EEE2857

P31

Q33819111-D22CD45D-AF42-41D2-9B28-7267CD048E9B

P356

Q33819111-52F332D1-5351-4294-BE73-5339E553D266

P407

Q33819111-FC1670A6-0781-4C1E-93F1-9D17DEF2EA33

P433

Q33819111-CBA93AA0-EA81-47B2-B70F-04557C7CCFED

P478

Q33819111-5685ECCF-8D99-4930-A7D0-4CB3AF01C7E7

P577

Q33819111-AEABE643-B8D7-450C-83DF-392A77438097

P5875

Q33819111-CB5B0F99-DA68-40A4-A653-E46141506CFC

P6179

Q33819111-08D83864-BCEA-45BC-B608-F25BF6761029

P698

Q33819111-56CF0ECF-EA7F-4D09-A04C-2E4165EBBAF3

P932

Q33819111-1A701EEF-6C43-4465-B17A-F3DB64ECBD1C

P356

S00198-009-1046-3

P1433

Osteoporosis International

P1476

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates

@en

P2093

A Abelson

http://www.w3.org/2001/XMLSchema#string

D T Gold

http://www.w3.org/2001/XMLSchema#string

J D Ringe

http://www.w3.org/2001/XMLSchema#string

J L Lange

http://www.w3.org/2001/XMLSchema#string

T Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

FRAX and the assessment of fracture probability in men and women from the UK

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Bias in the evaluation of low-magnitude associations: an empirical perspective.

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Evidence of bias in estimates of influenza vaccine effectiveness in seniors.

Population-based analysis of the relationship of whole bone strength indices and fall-related loads to age- and sex-specific patterns of hip and wrist fractures.

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

P2888

s00198-009-1046-3

P304

1021-1029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-009-1046-3

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26781721

http://www.w3.org/2001/XMLSchema#string

P6179

1008954345

http://www.w3.org/2001/XMLSchema#string

P698

19722103

http://www.w3.org/2001/XMLSchema#string

P932

2861765

http://www.w3.org/2001/XMLSchema#string